Semaglutide's Cardiovascular Benefits Remain Strong, Regardless of Aspirin Use
Background
Semaglutide, a potent GLP-1 receptor agonist, has revolutionized the management of type 2 diabetes and obesity, demonstrating significant cardiovascular protective effects. Aspirin is a well-established cornerstone in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet properties. This study aimed to determine if baseline aspirin use modified the robust cardiovascular benefits of semaglutide observed in two landmark clinical trials.
Results
The analysis revealed that semaglutide consistently reduced major adverse cardiovascular events (MACE) across both trials, irrespective of whether participants were on aspirin at baseline. In the overall pooled population, semaglutide led to a significant 20% reduction in MACE (Hazard Ratio [HR] 0.80, 95% Confidence Interval [CI] 0.73-0.88, p<0.001) compared to placebo. > The cardiovascular benefits of semaglutide were remarkably consistent, showing a 19% MACE reduction (HR 0.81, 95% CI 0.72-0.91) in patients receiving aspirin at baseline and an equally compelling 22% reduction (HR 0.78, 95% CI 0.68-0.89) in those not on aspirin, with no statistically significant interaction between treatment effect and aspirin use (p-interaction=0.65). This suggests that semaglutide's mechanisms of cardiovascular protection, which include improvements in glycemic control, weight loss, and direct vascular effects, are largely independent of aspirin's antiplatelet actions. Furthermore, the safety profile of semaglutide remained favorable, with no new safety signals or differential rates of serious adverse events observed across the aspirin use subgroups.
Why It Matters
These findings provide critical clinical guidance, underscoring that semaglutide's profound cardiovascular benefits are robust and complementary to, rather than dependent on, traditional antiplatelet therapy with aspirin. This reinforces semaglutide's position as a cornerstone therapy for comprehensive cardiovascular risk reduction in eligible patients, regardless of their current aspirin regimen. This strong evidence supports the expanded and confident use of semaglutide for cardiovascular protection across a broader spectrum of patients with established cardiovascular disease, both with and without type 2 diabetes. Future research could explore the long-term synergistic effects of combination therapies and optimal patient selection strategies.